PharmAthene to Host Year-End 2007 Earnings Conference Call and Webcast on Thursday, March 20, 2008

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

PharmAthene to Host Year-End 2007 Earnings Conference Call and Webcast on Thursday, March 20, 2008

    ANNAPOLIS, Md., March 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc.
(Amex: PIP) a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that its financial results
for the year ended 2007 will be released on Thursday, March 20, 2008.

    PharmAthene management will be hosting a conference call to discuss its
year end financial results. The call is scheduled to begin at 4:30 p.m.
Eastern Time on Thursday, March 20, 2008 and will last approximately 45
minutes.

    The dial-in number within the United States is 800-561-2813. The
dial-in number for international callers is 617-614-3529. The participant
passcode is 25398564.

    A replay of the conference call will be available for 30 days,
beginning at approximately 6:30 p.m. Eastern Time Thursday, March 20, 2008
until approximately 11:50 p.m. Eastern Time April 17, 2008. The dial-in
number from within the United States is 888-286-8010. For international
callers, the dial-in number is 617-801-6888. The participant passcode is
99739488.

    The conference call will also be webcast and can be accessed from the
company's website at http://www.pharmathene.com. A link to the webcast may
be found on both the Home Page and also under the Investor Relations
section of the website. The webcast will be available for 30 days, or until
approximately Thursday, April 17, 2008.

    About PharmAthene, Inc

    PharmAthene (Amex: PIP) was formed to meet the critical needs of the
United States and its allies by developing and commercializing medical
countermeasures against biological and chemical weapons. PharmAthene's lead
programs include Valortim(TM) for the prevention and treatment of anthrax
infection and Protexia(R) for the prevention and treatment of morbidity and
mortality associated with exposure to chemical nerve agents. For more
information on PharmAthene, please visit http://www.PharmAthene.com.

SOURCE PharmAthene, Inc.

http://www.pharmathene.com
CONTACT:
Stacey Jurchison of PharmAthene, Inc.,
+1-410-269-2610, JurchisonS@PharmAthene.com